Saturday, June 13, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 1062 of 1,261
  1. US 7358087

    Compositions and methods for enhancing immune responses mediated by antigen-presenting cells

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  2. US 7358085

    Anti-angiogenic methods and compositions

    Sangamo Biosciences, Inc. · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  3. US 7358222

    Preventing airway mucus production by administration of EGF-R antagonists

    The Regents of the University of California · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  4. US 7358258

    Prodrugs of an ERK protein kinase inhibitor

    Vertex Pharmaceuticals Incorporated · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  5. US 7358260

    Quinuclidine derivatives and medicinal compositions containing the same

    Laboratories Almirall, S.A. · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  6. US 7358377

    Schweinfurthin analogues

    The United States of America · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  7. US 7358273

    Inhibitors of caspases

    Vertex Pharmaceuticals Incorporated · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  8. US 7358390

    Polymorphic forms of nateglinide

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  9. US 7358360

    Risedronate sodium having a very low content of iron

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  10. US 7358364

    Substituted carboxylic acids

    The Institute for Pharmaceutical Discovery, LLC · Granted Apr 15, 2008 · Expires Apr 10, 2028

    granted
  11. DE 102006048130

    Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil

    AXXONIS PHARMA AG [DE] · Granted Apr 10, 2008 · Expires Apr 5, 2028

    granted
  12. US 7354580

    Method of administering and using VEGF inhibitors for the treatment of human cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  13. US 7354579

    Method of treating cancer with a VEGF antagonist and an anti-proliferative agent

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  14. US 7354578

    Method of tumor regression with VEGF inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  15. US 7354576

    Methods of treating diseases caused by deficiencies of recombinant α-L-iduronidase

    BIOMARIN PHARMACEUTICAL INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  16. US 7353829

    Methods and apparatus for multi-photon photo-activation of therapeutic agents

    Provectus Devicetech, Inc. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  17. US 7354900

    Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides

    The Board of Regents of the University of Oklahoma · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  18. US 7355079

    Thyronamine derivatives and analogs and methods of use thereof

    The Regents of the University of California · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  19. US 7355047

    Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

    The Regents of the University of California · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  20. US 7355012

    Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  21. US 7354909

    Method for rapid generation of mature dendritic cells

    UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  22. US 7354581

    Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  23. US 7354894

    Preventing airway mucus production by administration of EGF-R antagonists

    The Regents of the University of California · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted
  24. US 7354582

    Use of VEGF antagonists for the treatment of malignant gliomas

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2008 · Expires Apr 3, 2028

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.